Publications

Polygenic Risk Score in a cohort of 105 Breast Cancer patients previously tested with a multi gene panel for hereditary cancer.

Next Generation Sequencing (NGS) for the identification of PARP inhibitors’ predictive biomarkers

Cascade genetic testing utilized only in 31% of initial families with pathogenic variants in breast cancer genes

Copy Number Variations (CNVs) and Hereditary Breast Cancer

Multigene panel testing results for hereditary breast cancer - ESMO 2019

Tumor Mutational Burden TMB - poster at ECCB 2018

Analysis of hereditary cancer syndromes by use of a panel of genes: More answers than questions.

BRCA Early Access program - poster at ECP

CTRC-AACR San Antonio Breast Cancer Symposium 2014

St. Gallen 2013 OncotypeDX

St. Gallen 2011

EANO 2012

ASCO 2012 EGFR

ASCO 2012 ALK

St. Gallen 2011

ESMO 2011 ALK

ESMO 2011 EGFR

Different Copy Number Variations (CNVs) account for 10.4% of pathogenic variants in 1418 patients referred for hereditary breast cancer testing

Meme Kanseri, Kolorektal Kanser, Tiroit Kanseri, Melanom ve Böbrek Hücreli Karsinom gibi çeşitli kalıtsal kanser tiplerinden sorumlu mutasyonların tespiti için günümüzde genetik testler yapılabilmektedir.